Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ana Izquierdo Gil"'
Autor:
Maarten Swart, Harmjan Kuipers, Fin Milder, Mandy Jongeneelen, Tina Ritschel, Jeroen Tolboom, Leacky Muchene, Joan van der Lubbe, Ana Izquierdo Gil, Daniel Veldman, Jeroen Huizingh, Johan Verspuij, Sonja Schmit-Tillemans, Sven Blokland, Martijn de Man, Ramon Roozendaal, Christopher B. Fox, Hanneke Schuitemaker, Martinus Capelle, Johannes P. M. Langedijk, Roland Zahn, Boerries Brandenburg
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-14 (2023)
Abstract Seasonal influenza vaccines must be updated annually and suboptimally protect against strains mismatched to the selected vaccine strains. We previously developed a subunit vaccine antigen consisting of a stabilized trimeric influenza A group
Externí odkaz:
https://doaj.org/article/c69a4a5a06604a7aad8ce772de4658bd
Autor:
Maarten Swart, Joan van der Lubbe, Sonja Schmit-Tillemans, Ella van Huizen, Johan Verspuij, Ana Izquierdo Gil, Ying Choi, Chenandly Daal, Aditya Perkasa, Adriaan de Wilde, Erwin Claassen, Rineke de Jong, Katrin E. Wiese, Lisette Cornelissen, Marieke van Es, Marjolein van Heerden, Eleni Kourkouta, Issam Tahiri, Michel Mulders, Jessica Vreugdenhil, Karin Feddes - de Boer, Leacky Muchene, Jeroen Tolboom, Liesbeth Dekking, Jarek Juraszek, Jort Vellinga, Jerome Custers, Rinke Bos, Hanneke Schuitemaker, Frank Wegmann, Ramon Roozendaal, Harmjan Kuipers, Roland Zahn
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract Since the original outbreak of the SARS-CoV-2 virus, several rapidly spreading SARS-CoV-2 variants of concern (VOC) have emerged. Here, we show that a single dose of Ad26.COV2.S (based on the Wuhan-Hu-1 spike variant) protects against the Ga
Externí odkaz:
https://doaj.org/article/225f12fc050d4eedbec35ffc6652125e
Autor:
Selina Khan, Nadine C. Salisch, Ana Izquierdo Gil, Satish Boedhoe, Karin Feddes-de Boer, Jan Serroyen, Hanneke Schuitemaker, Roland C. Zahn
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-13 (2022)
Abstract The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to
Externí odkaz:
https://doaj.org/article/d491b13699db469ebcfbd2dc8b441508
Autor:
Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, Ying Choi, Miranda R. M. Baert, Karin Feddes-de Boer, Ana Izquierdo Gil, Marjolein van Heerden, Tim J. Dalebout, Sebenzile K. Myeni, Marjolein Kikkert, Eric J. Snijder, Leon de Waal, Koert J. Stittelaar, Jeroen T. B. M. Tolboom, Jan Serroyen, Leacky Muchene, Leslie van der Fits, Lucy Rutten, Johannes P. M. Langedijk, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human
Externí odkaz:
https://doaj.org/article/fc2cb2bea71d44b4a49590c0dc2b55f2
Autor:
Maarten Swart, Adriaan de Wilde, Sonja Schmit-Tillemans, Johan Verspuij, Chenandly Daal, Ying Choi, Aditya Perkasa, Eleni Kourkouta, Issam Tahiri, Michel Mulders, Ana Izquierdo Gil, Leacky Muchene, Jarek Juraszek, Jort Vellinga, Jerome Custers, Rinke Bos, Hanneke Schuitemaker, Frank Wegmann, Ramon Roozendaal, Harmjan Kuipers, Roland Zahn
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant sparked concern due to its fast spread and the unprecedented number of mutations in the spike protein that enables it to partially evade spike-based COVID-19 vaccine-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68926e9d55900502baafcc4a2b6a678b
https://doi.org/10.1101/2022.03.04.482636
https://doi.org/10.1101/2022.03.04.482636
Autor:
Jerome Custers, Jessica Vreugdenhil, Roland Zahn, Adriaan H. de Wilde, Frank Wegmann, Babs E. Verstrepen, Ella van Huizen, Ivanela Kondova, Joan E.M. van der Lubbe, Jeroen Tolboom, Joke Drijver, Mandy Jongeneelen, Joost Vaneman, Dominika N. Czapska-Casey, Laura Solforosi, Eric J. Snijder, Willy M. J. M. Bogers, Miranda R.M. Baert, Daniel Veldman, Kinga P. Böszörményi, Hanneke Schuitemaker, Leacky Muchene, Eleni Kourkouta, Harmjan Kuipers, Ying Choi, Ernst J. Verschoor, Ana Izquierdo Gil, Marjolein van Heerden, Marieke A. Stammes, Tim J. Dalebout, Liesbeth Dekking, Petra Mooij, Krisztian Kaszas, Ramon Roozendaal, Sanne Kroos, Sebenzile K. Myeni, Jeroen Huizingh, Remko Van Der Vlugt, Boerries Brandenburg, Marjolein Kikkert, Sietske K. Rosendahl Huber, Gerrit Koopman, Dan H. Barouch
Publikováno v:
Journal of Experimental Medicine
The Journal of Experimental Medicine
Journal of Experimental Medicine, 218(7). ROCKEFELLER UNIV PRESS
The Journal of Experimental Medicine
Journal of Experimental Medicine, 218(7). ROCKEFELLER UNIV PRESS
While single-dose COVID-19 vaccines are preferred, two-dose regimens may improve efficacy. Immunogenicity of Ad26.COV2.S is improved in NHPs after a second dose, whereas both regimens protect animals against SARS-CoV-2 disease and elicit neutralizing
Autor:
Lucy Rutten, Tim J. Dalebout, Liesbeth Dekking, Dan H. Barouch, Koert J. Stittelaar, Hanneke Schuitemaker, Frank Wegmann, Marjolein van Heerden, Joan E.M. van der Lubbe, Roland Zahn, Jessica Vreugdenhil, Sebenzile K. Myeni, Johannes P. M. Langedijk, Ella van Huizen, Miranda R.M. Baert, Leacky Muchene, Jan Serroyen, Marjolein Kikkert, Jeroen Tolboom, Ana Izquierdo Gil, Ying Choi, Sietske K. Rosendahl Huber, Karin Feddes-de Boer, Aneesh Vijayan, Leon de Waal, Eric J. Snijder, Leslie van der Fits
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aebc400ef746539a4e9acf90c43787e1
https://doi.org/10.1101/2021.01.08.425915
https://doi.org/10.1101/2021.01.08.425915
Autor:
Marquez-Martinez, Sonia1 (AUTHOR), Salisch, Nadine1 (AUTHOR), Serroyen, Jan1 (AUTHOR), Zahn, Roland1 (AUTHOR) RZahn@its.jnj.com, Khan, Selina1 (AUTHOR)
Publikováno v:
PLoS ONE. 4/16/2024, Vol. 19 Issue 4, p1-20. 20p.
Autor:
Swart, Maarten, Kuipers, Harmjan, Milder, Fin, Jongeneelen, Mandy, Ritschel, Tina, Tolboom, Jeroen, Muchene, Leacky, van der Lubbe, Joan, Izquierdo Gil, Ana, Veldman, Daniel, Huizingh, Jeroen, Verspuij, Johan, Schmit-Tillemans, Sonja, Blokland, Sven, de Man, Martijn, Roozendaal, Ramon, Fox, Christopher B., Schuitemaker, Hanneke, Capelle, Martinus, Langedijk, Johannes P. M.
Publikováno v:
NPJ Vaccines; 11/11/2023, Vol. 8 Issue 1, p1-14, 14p
Autor:
Swart, Maarten, van der Lubbe, Joan, Schmit-Tillemans, Sonja, van Huizen, Ella, Verspuij, Johan, Gil, Ana Izquierdo, Choi, Ying, Daal, Chenandly, Perkasa, Aditya, de Wilde, Adriaan, Claassen, Erwin, de Jong, Rineke, Wiese, Katrin E., Cornelissen, Lisette, van Es, Marieke, van Heerden, Marjolein, Kourkouta, Eleni, Tahiri, Issam, Mulders, Michel, Vreugdenhil, Jessica
Publikováno v:
NPJ Vaccines; 3/16/2023, Vol. 8 Issue 1, p1-12, 12p